Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Mutiple-dose Study of IBI3033 in Healthy Participants
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 8-week treatment period and 8-week follow-up period.
Official title: A Randomized, Double-blind, Placebo-controlled, Mutiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IBI3033 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2026-03-24
Completion Date
2026-11-13
Last Updated
2026-03-09
Healthy Volunteers
Yes
Conditions
Interventions
Placebo
Participants in placebo group will receive placebo SC.
IBI3033
Participants in IBI3033 group will receive multiple doses of IBI3033 SC at the protocol specified dose level and time points.
Locations (1)
Shanghai General Hospital
Shanghai, Shanghai Municipality, China